Soleus Capital Management L.P. Purchases Shares of 801,000 Delcath Systems, Inc. (NASDAQ:DCTH)

Soleus Capital Management L.P. purchased a new stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 801,000 shares of the company's stock, valued at approximately $9,644,000. Soleus Capital Management L.P. owned about 2.51% of Delcath Systems at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of DCTH. Barclays PLC acquired a new position in shares of Delcath Systems during the 3rd quarter valued at about $104,000. Baader Bank Aktiengesellschaft acquired a new position in shares of Delcath Systems during the 4th quarter valued at about $204,000. Principal Financial Group Inc. boosted its position in shares of Delcath Systems by 28.8% during the 4th quarter. Principal Financial Group Inc. now owns 115,183 shares of the company's stock valued at $1,387,000 after acquiring an additional 25,736 shares during the last quarter. Private Advisor Group LLC acquired a new position in Delcath Systems in the fourth quarter valued at about $153,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Delcath Systems in the fourth quarter valued at about $156,000. Institutional investors and hedge funds own 61.12% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on DCTH. Wall Street Zen raised shares of Delcath Systems from a "buy" rating to a "strong-buy" rating in a research report on Saturday. HC Wainwright upped their target price on shares of Delcath Systems from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Friday. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $24.00.

Delcath Systems Stock Down 0.2%

Shares of NASDAQ DCTH traded down $0.04 during mid-day trading on Friday, hitting $16.11. 551,896 shares of the company were exchanged, compared to its average volume of 371,106. The stock has a 50 day simple moving average of $13.05 and a 200-day simple moving average of $12.96. Delcath Systems, Inc. has a 1-year low of $6.33 and a 1-year high of $18.23. The firm has a market cap of $561.05 million, a price-to-earnings ratio of -11.93 and a beta of 0.72.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.07). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. The company had revenue of $19.80 million for the quarter, compared to analyst estimates of $16.83 million. Analysts anticipate that Delcath Systems, Inc. will post -0.79 earnings per share for the current fiscal year.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.